{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T11:40:02Z","timestamp":1736163602307,"version":"3.32.0"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,6]]},"DOI":"10.7759\/cureus.76993","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T10:30:11Z","timestamp":1736159411000},"source":"Crossref","is-referenced-by-count":0,"title":["Severe Reversible Heart Failure Enhanced by Sorafenib Treatment for Hepatocellular Carcinoma"],"prefix":"10.7759","author":[{"given":"Lu\u00eds Guilherme","family":"Santos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"Roque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Antunes Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catarina","family":"Neves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuno","family":"Bonito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet JM","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, et al.. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008, 359:378-90. 10.1056\/NEJMoa0708857","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng AL","year":"2009","unstructured":"Cheng AL, Kang YK, Chen Z, et al.. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009, 10:25-34. 10.1016\/S1470-2045(08)70285-7","journal-title":"Lancet Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/7065759","article-title":"Sorafenib-associated heart failure complicated by cardiogenic shock after treatment of advanced-stage hepatocellular carcinoma: a clinical case discussion","volume":"2017","author":"Wu C","year":"2017","unstructured":"Wu C, Shemisa K. Sorafenib-associated heart failure complicated by cardiogenic shock after treatment of advanced-stage hepatocellular carcinoma: a clinical case discussion. Case Rep Cardiol. 2017, 2017:7065759. 10.1155\/2017\/7065759","journal-title":"Case Rep Cardiol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2023.2251398","article-title":"Cardiovascular toxicities following the use of tyrosine kinase inhibitors in hepatocellular cancer patients: a retrospective, pharmacovigilance study","volume":"23","author":"Lai X","year":"2024","unstructured":"Lai X, Wan Q, Jiao SF, Sun XC, Hu JF, Peng HW. Cardiovascular toxicities following the use of tyrosine kinase inhibitors in hepatocellular cancer patients: a retrospective, pharmacovigilance study. Expert Opin Drug Saf. 2024, 23:287-96. 10.1080\/14740338.2023.2251398","journal-title":"Expert Opin Drug Saf"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S443107","article-title":"Understanding sorafenib-induced cardiovascular toxicity: mechanisms and treatment implications","volume":"18","author":"Li J","year":"2024","unstructured":"Li J, Zhang L, Ge T, Liu J, Wang C, Yu Q. Understanding sorafenib-induced cardiovascular toxicity: mechanisms and treatment implications. Drug Des Devel Ther. 2024, 18:829-43. 10.2147\/DDDT.S443107","journal-title":"Drug Des Devel Ther"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2011.12.114","article-title":"A case of reversible cardiomyopathy associated with sorafenib in advanced hepatocellular carcinoma","volume":"160","author":"Park H","year":"2012","unstructured":"Park H, Han SH, Kang H, Park K. A case of reversible cardiomyopathy associated with sorafenib in advanced hepatocellular carcinoma. Int J Cardiol. 2012, 160:e10-1. 10.1016\/j.ijcard.2011.12.114","journal-title":"Int J Cardiol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1108849","article-title":"Reversible cardiomyopathy associated with sunitinib and sorafenib","volume":"365","author":"Uraizee I","year":"2011","unstructured":"Uraizee I, Cheng S, Moslehi J. Reversible cardiomyopathy associated with sunitinib and sorafenib. N Engl J Med. 2011, 365:1649-50. 10.1056\/NEJMc1108849","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/332681-severe-reversible-heart-failure-enhanced-by-sorafenib-treatment-for-hepatocellular-carcinoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T10:30:12Z","timestamp":1736159412000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/332681-severe-reversible-heart-failure-enhanced-by-sorafenib-treatment-for-hepatocellular-carcinoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,6]]},"references-count":7,"URL":"https:\/\/doi.org\/10.7759\/cureus.76993","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,6]]}}}